

Quadrol-Pd(II) complexes: phosphine-free precatalysts for the room-temperature Suzuki- Miyaura synthesis of nucleoside analogues in aqueous media

José Luis Serrano,^{a,} Sujeet Gaware^b, Jose Antonio Pérez,^a José Pérez,^a Pedro Lozano^c, Santosh
Kori,^{b,d} Rambabu Dandela^b, Yogesh S. Sanghvi^e, Anant R. Kapdi^{d,*}*

^a Departamento de Ingeniería Química y Ambiental. Área de Química Inorgánica, Universidad Politécnica de Cartagena member of European University of Technology, 30203 Cartagena, Spain

^b Department of Chemistry, Institute of Chemical Technology-Indian Oil Odisha Campus, IIT Kharagpur Extension Centre, Mouza Samantpuri, Bhubaneswar 751013, Odisha, India.

^c Departamento de Bioquímica y Biología Molecular B e Inmunología, Facultad de Química, Regional Campus of International Excellence “Campus Mare Nostrum”, Universidad de Murcia, 30071 Murcia, Spain.

^d Department of Chemistry, Institute of Chemical Technology, Mumbai, Nathalal Road, Matunga, Mumbai-400019, India

^e Rasayan Inc. 2802, Crystal Ridge Road, Encinitas, California, 92024-6615, United States of America)


Supporting Information.

1). Data related to nucleosides: NMR and references..... S3


2). Spectroscopic characterization of complexes.....S19

Data related to nucleoside: NMR and Spectra

1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-(m-tolyl)pyrimidine-2,4(1H,3H)-dione (7a) (133mg 84%). ¹H NMR (500 MHz, DMSO) δ 11.49 (s, 1H), 8.19 (s, 1H), 7.39 – 7.32 (m, 2H), 7.26 (t, *J* = 7.6 Hz, 1H), 7.12 (d, *J* = 7.5 Hz, 1H), 6.25 (t, *J* = 6.6 Hz, 1H), 5.27 (d, *J* = 4.2 Hz, 1H), 5.12 (t, *J* = 4.8 Hz, 1H), 4.31 (dd, *J* = 5.3, 3.6 Hz, 1H), 3.83 (q, *J* = 2.9 Hz, 1H), 3.68 – 3.55 (m, 2H), 2.33 (s, 3H), 2.26 (dt, *J* = 13.1, 6.5 Hz, 1H), 2.17 (ddd, *J* = 13.3, 6.2, 3.7 Hz, 1H). ¹³C NMR{¹H} (126 MHz, DMSO) δ 162.5, 150.3, 138.3, 137.5, 133.5, 128.9, 128.4, 128.2, 125.5, 114.0, 87.9, 84.9, 70.6, 61.4, 40.5, 21.5. **Anal calcd.** for C₁₆H₁₈N₂O₅: C, 60.37; H, 5.70; N, 8.80. Found C, 60.36; H, 5.80; N, 8.70.




1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-(4-methylthio)phenylpyrimidine-2,4(1H,3H)-dione (7b) (0.126 g, 72%) :- ^1H NMR (500 MHz, DMSO) δ 11.50 (s, 1H), 8.21 (s, 1H), 7.51 (d, J = 8.4 Hz, 2H), 7.26 (d, J = 8.4 Hz, 2H), 6.24 (t, J = 6.6 Hz, 1H), 5.33 (d, J = 4.0 Hz, 1H), 5.17 (t, J = 4.5 Hz, 1H), 4.30 (s, 1H), 3.83 (d, J = 2.9 Hz, 1H), 3.65 – 3.57 (m, 2H), 2.48 (s, 3H), 2.25 (dt, J = 13.0, 6.4 Hz, 1H), 2.17 (ddd, J = 13.3, 6.0, 3.8 Hz, 1H). ^{13}C NMR{ ^1H } (126 MHz, DMSO) δ 162.5, 150.3, 138.0, 137.5, 130.1, 128.7, 126.1, 113.3, 87.9, 84.9, 70.6, 61.4, 40.5, 15.1. The spectral data were in accordance with those reported in the literature¹.




1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-(3-methoxyphenyl)pyrimidine-2,4(1H,3H)-dione (7c) :- (0.125 g , 75%) ^1H NMR (400 MHz, DMSO) δ 11.49 (s, 1H), 8.22 (s, 1H), 7.30 – 7.25 (m, 1H), 7.16 – 7.13 (m, 2H), 6.89 – 6.85 (m, 1H), 6.25 (t, J = 6.6 Hz, 1H), 5.27 (d, J = 4.3 Hz, 1H), 5.12 (t, J = 5.0 Hz, 1H), 4.31 (td, J = 7.3, 3.7 Hz, 1H), 3.87 – 3.81 (m, 1H), 3.76 (s, 3H), 3.67 – 3.57 (m, 2H), 2.29 – 2.22 (m, 1H), 2.18 (ddd, J = 13.3, 6.3, 3.7 Hz, 1H). ^{13}C NMR{ ^1H } (101 MHz, DMSO) δ 162.4, 159.4, 150.3, 138.6, 134.9, 129.5, 120.6, 113.8, 113.2, 88.0, 85.0, 70.7, 61.4, 55.4, 40.6. The spectral data were in accordance with those reported in the literature².


SJG-DU-04-1H.10.fid
SJG-DU-04-1H





SJG-DU-04-13C.12.fid
SJG-DU-04-13C





5-(3,5-dimethylphenyl)-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione (7d) :- (0.116 g, 70%) ¹H NMR (500 MHz, DMSO) δ 11.47 (s, 1H), 8.16 (s, 1H), 7.16 (s, 2H), 6.94 (s, 1H), 6.24 (t, *J* = 6.6 Hz, 1H), 5.27 (d, *J* = 4.3 Hz, 1H), 5.11 (t, *J* = 4.9 Hz, 1H), 4.31 (dq, *J* = 7.7, 3.8 Hz, 1H), 3.82 (q, *J* = 3.1 Hz, 1H), 3.62 (qdd, *J* = 11.8, 4.7, 3.4 Hz, 2H), 2.28 (s, 6H), 2.25 (dd, *J* = 13.4, 6.7 Hz, 1H), 2.17 (ddd, *J* = 13.3, 6.2, 3.7 Hz, 1H). ¹³C NMR{¹H} (126 MHz, DMSO) δ 162.5, 150.3, 138.2, 137.4, 133.4, 129.0, 126.1, 114.1, 87.9, 84.8, 70.59, 61.3, 40.5, 21.4. The spectral data were in accordance with those reported in the literature¹.




5-(benzo[c][1,2,5]oxadiazol-5-yl)-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione (7e) :- (0.125 g, 72%) ^1H NMR (500 MHz, DMSO) δ 11.71 (s, 1H), 8.54 (s, 1H), 8.22 (s, 1H), 8.00 (d, J = 9.5 Hz, 1H), 7.78 (dd, J = 9.5, 1.0 Hz, 1H), 6.22 (t, J = 6.4 Hz, 1H), 5.41 (d, J = 4.0 Hz, 1H), 5.33 (t, J = 4.4 Hz, 1H), 4.33 (s, 1H), 3.85 (dd, J = 6.3, 3.0 Hz, 1H), 2.37 – 2.26 (m, 1H), 2.24 – 2.16 (m, 1H). ^{13}C NMR $\{^1\text{H}\}$ (126 MHz, DMSO) δ 162.3, 150.1, 149.6, 148.4, 140.8, 137.8, 134.1, 115.7, 112.9, 111.5, 88.0, 85.4, 70.2, 61.1, 40.6. **Anal calcd.** For $\text{C}_{15}\text{H}_{14}\text{N}_4\text{O}_6$: C, 52.03; H, 4.08; N, 16.18; Found: C, 52.05; H, 4.05; N, 16.33.




5-([1,1'-biphenyl]-4-yl)-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione (7f) :- (0.118 g, 62%) ^1H NMR (500 MHz, DMSO) δ 11.17 (s, 1H), 8.30 (s, 1H), 7.69 (d, J = 11.0 Hz, 6H), 7.49 (t, J = 7.6 Hz, 2H), 7.38 (t, J = 7.3 Hz, 1H), 6.28 (t, J = 6.6 Hz, 1H), 5.31 (s, 1H), 5.18 (s, 1H), 4.33 (s, 1H), 3.85 (d, J = 2.9 Hz, 1H), 3.65 (dd, J = 25.4, 11.6 Hz, 2H), 2.29 (dt, J = 13.0, 6.4 Hz, 1H), 2.20 (ddd, J = 13.2, 6.0, 3.7 Hz, 1H). ^{13}C NMR $\{^1\text{H}\}$ (126 MHz, DMSO) δ 162.6, 150.3, 140.2, 139.3, 138.4, 132.8, 129.4, 128.8, 127.9, 126.9, 126.8, 113.4, 88.0, 85.0, 70.6, 61.4, 40.5. The spectral data were in accordance with those reported in the literature¹.





5-(benzofuran-3-yl)-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione (7g) :- (0.117 g, 68%) ¹H NMR (400 MHz, DMSO) δ 11.74 (s, 1H), 8.73 (s, 1H), 7.60 (d, *J* = 7.3 Hz, 1H), 7.53 (d, *J* = 8.1 Hz, 1H), 7.32 (s, 1H), 7.24 (ddd, *J* = 25.1, 11.2, 4.0 Hz, 2H), 6.22 (t, *J* = 6.4 Hz, 1H), 5.34 (d, *J* = 4.2 Hz, 1H), 5.25 (t, *J* = 4.2 Hz, 1H), 4.37 – 4.30 (m, 1H), 3.87 (q, *J* = 3.0 Hz, 1H), 3.74 – 3.64 (m, 2H), 2.23 (dd, *J* = 8.4, 4.2 Hz, 2H). ¹³C NMR{¹H} (101 MHz, DMSO) δ 160.7, 153.4, 149.8, 149.5, 137.5, 129.2, 124.7, 123.4, 121.4, 111.2, 105.1, 104.3, 88.1, 85.5, 70.5, 61.3, 40.9. **Anal Calcd.** For C₁₆H₁₆N₂O₆ C, 59.30; H, 4.68; N, 8.14. Found C, 59.31; H, 4.54; N, 8.20





AK-JA-DU-08-13C.1.fid
AK-JA-DU-08-13C




5-(4-fluorophenyl)-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione (7h) :- (0.077 g, 48%) ¹H NMR (400 MHz, DMSO) δ 11.43 (s, 1H), 8.19 (s, 1H), 7.59 – 7.54 (m, 2H), 7.21 – 7.14 (m, 2H), 6.21 (t, J = 6.6 Hz, 1H), 5.27 (d, J = 2.7 Hz, 1H), 5.13 (s, 1H), 4.28 (s, 1H), 3.80 (q, J = 2.9 Hz, 1H), 3.64 – 3.54 (m, 2H), 2.24 (dt, J = 13.0, 6.4 Hz, 1H), 2.15 (ddd, J = 13.3, 6.2, 3.8 Hz, 1H). ¹³C NMR{¹H} (101 MHz, DMSO), 162.5, 161.8(d, J_{CF} = 245.4 Hz), 150.3, 138.4, 130.3(d, J_{CF} = 8.0 Hz), 130.0 (d, J_{CF} = 3.0 Hz), 115.4 (d, J_{CF} = 21 Hz), 112.9, 87.9, 85.0, 70.6, 61.3, 40.5. The spectral data were in accordance with those reported in the literature².



1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-(naphthalen-2-yl)pyrimidine-2,4(1H,3H)-dione 7i :- (0.109 g, 62%) ¹H NMR (400 MHz, DMSO) δ 11.57 (s, 1H), 8.36 (s, 1H), 8.12 (s, 1H), 7.95 – 7.85 (m, 3H), 7.68 (dd, *J* = 8.6, 1.6 Hz, 1H), 7.53 – 7.44 (m, 2H), 6.26 (t, *J* = 6.5 Hz, 1H), 5.29 (d, *J* = 4.3 Hz, 1H), 5.18 (t, *J* = 4.7 Hz, 1H), 4.37 – 4.27 (m, 1H), 3.87 – 3.81 (m, 1H), 3.70 – 3.55 (m, 2H), 2.29 (dt, *J* = 13.0, 6.4 Hz, 1H), 2.19 (ddd, *J* = 13.3, 6.2, 3.9 Hz, 1H). ¹³C NMR{¹H} (101 MHz, DMSO) δ 162.7, 150.4, 138.9, 133.3, 132.5, 131.2, 128.4, 127.8, 126.9, 126.6, 126.6, 126.4, 113.7, 88.0, 85.1, 70.6, 61.3, 40.6. The spectral data were in accordance with those reported in the literature².




1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-(4-methoxyphenyl)pyrimidine-2,4(1H,3H)-dione (7j) :- (0.127 g, 76%) ¹H NMR (400 MHz, DMSO) δ 11.44 (s, 1H), 8.09 (s, 1H), 7.46 (d, *J* = 8.8 Hz, 2H), 6.91 (d, *J* = 8.8 Hz, 2H), 6.22 (t, *J* = 6.6 Hz, 1H), 5.26 (d, *J* = 4.2 Hz, 1H), 5.10 (t, *J* = 4.8 Hz, 1H), 4.27 (dd, *J* = 5.2, 3.6 Hz, 1H), 3.80 (d, *J* = 3.1 Hz, 1H), 3.74 (s, 3H), 3.65 – 3.52 (m, 2H), 2.22 (dt, *J* = 13.1, 6.4 Hz, 1H), 2.13 (ddd, *J* = 13.3, 6.2, 3.6 Hz, 1H). ¹³C NMR{¹H} (101 MHz, DMSO) δ 162.7, 158.9, 150.3, 137.4, 129.5, 125.8, 114.0, 113.7, 87.9, 84.8, 70.7, 61.4, 55.5, 40.5. The spectral data were in accordance with those reported in the literature².




1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-(3-nitrophenyl)pyrimidine-2,4(1H,3H)-dione (7k) :- (0.143 g, 82%) ¹H NMR (400 MHz, DMSO) δ 11.67 (s, 1H), 8.51 (t, *J* = 2.0 Hz, 1H), 8.46 (s, 1H), 8.15 (ddd, *J* = 8.2, 2.3, 0.9 Hz, 1H), 8.00 – 7.96 (m, 1H), 7.66 (t, *J* = 8.0 Hz, 1H), 6.22 (t, *J* = 6.4 Hz, 1H), 5.31 (d, *J* = 4.3 Hz, 1H), 5.20 (t, *J* = 4.8 Hz, 1H), 4.32 (dq, *J* = 8.0, 4.0 Hz, 1H), 3.84 (q, *J* = 3.1 Hz, 1H), 3.69 – 3.57 (m, 2H), 2.30 (dt, *J* = 12.8, 6.3 Hz, 1H), 2.20 (ddd, *J* = 13.4, 6.3, 4.1 Hz, 1H). ¹³C NMR{¹H} (101 MHz, DMSO) δ 162.4, 150.2, 148.1, 140.0, 135.4, 134.3, 130.1, 122.8,

122.2, 111.4, 88.0, 85.3, 70.3, 61.2, 40.7. The spectral data were in accordance with those reported in the literature².

SJG-DU-12-1H.10.fid
SJG-DU-09-1H




SJG-DU-12-13C.12.fid
SJG-DU-09-13C




4-amino-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-(m-tolyl)pyrimidin-2(1H)-one (9a) :- (0.114 g, 72%) ¹H NMR (500 MHz, DMSO) δ 7.87 (s, 1H), 7.43 (s, 1H), 7.32 (t, *J* = 7.6 Hz, 1H), 7.20 – 7.15 (m, 2H), 7.13 (d, *J* = 7.6 Hz, 1H), 6.37 (s, 1H), 6.22 (t, *J* = 6.5 Hz, 1H), 5.23 (s, 1H), 4.99 (s, 1H), 4.24 (s, 1H), 3.79 (d, *J* = 3.2 Hz, 1H), 3.55 (dd, *J* = 27.5, 11.6 Hz, 2H), 2.35 (s, 3H), 2.17 (ddd, *J* = 12.9, 5.8, 3.8 Hz, 1H), 2.09 (dt, *J* = 13.1, 6.5 Hz, 1H). ¹³C NMR{¹H} (126 MHz, DMSO) δ

163.7, 154.8, 140.4, 138.6, 134.2, 129.8, 129.3, 128.7, 126.2, 108.2, 87.7, 85.5, 70.6, 61.4, 41.0, 21.5.
Anal Calcd. For C₁₆H₁₉N₃O₄: C, 60.56; H, 6.04; N, 13.24. Found C, 60.40; H, 6.22; N, 13.37.



4-amino-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-(3-methoxyphenyl)pyrimidin-2(1H)-one (9b) :- (0.106 g, 64%) ¹H NMR (400 MHz, DMSO) δ 7.88 (d, *J* = 2.8 Hz, 392H), 7.35 (s, 1H), 7.32 (dd, *J* = 9.2, 6.5 Hz, 626H), 6.89 (tt, *J* = 3.6, 2.0 Hz, 1449H), 6.41 (s, 198H), 6.23 – 6.15 (m, 457H), 5.26 (d, *J* = 11.4 Hz, 209H), 5.04 – 4.97 (m, 294H), 4.24 – 4.17 (m, 1H),


3.79 – 3.76 (m, 1H), 3.76 (s, 2199H), 3.60 – 3.51 (m, 1H), 2.15 (ddd, $J = 13.3, 6.0, 3.7$ Hz, 761H), 2.10 – 2.02 (m, 1277H). ^{13}C NMR $\{^1\text{H}\}$ (101 MHz, DMSO) δ 163.6, 159.9, 154.8, 140.5, 135.5, 130.5, 121.3, 114.4, 114.0, 108.1, 87.7, 85.6, 70.5, 61.4, 55.4, 41.0. The spectral data were in accordance with those reported in the literature¹.




4-amino-5-(3,4-dimethoxyphenyl)-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (9c) :- (0.119 g, 66%) ^1H NMR (400 MHz, DMSO) δ 7.87 (s, 1H), 7.45 (s, 1H), 7.00 (d, $J = 8.1$ Hz, 1H), 6.94 – 6.77 (m, 2H), 6.51 (s, 1H), 6.21 (t, $J = 6.2$ Hz, 1H), 5.27 (s, 1H), 5.02 (s,

1H), 4.24 (s, 1H), 3.78 (s, 7H), 2.23 – 2.13 (m, 1H), 2.09 (dt, J = 12.8, 6.3 Hz, 1H). ¹³C NMR{¹H} (101 MHz, DMSO) δ 41.0, 55.8, 56.0, 61.4, 70.5, 85.6, 87.7, 108.2, 112.6, 112.9, 121.4, 126.3, 140.2, 148.8, 149.3, 154.7, 163.7. **Anal calcd.** For C₁₇H₂₁N₃O₆: C, 56.19; H, 5.83; N, 11.56; found C, 56.33; H, 5.83; N, 11.45.

ARK-dC-03-1H.1.fid
ARK-dC-03-1H




ARK-dC-03-13C.3.fid
ARK-dC-03-13C



4-amino-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-(3-(methylthio)phenyl)pyrimidin-2(1H)-one (9d) :- (0.155 g, 66%) ¹H NMR (500 MHz, DMSO) δ 7.89

(s, 1H), 7.40 (d, $J = 17.4$ Hz, 1H), 7.36 (t, $J = 7.7$ Hz, 1H), 7.25 (d, $J = 8.0$ Hz, 1H), 7.18 (s, 1H), 7.11 (d, $J = 7.6$ Hz, 1H), 6.48 (s, 1H), 6.22 (t, $J = 6.5$ Hz, 1H), 5.23 (d, $J = 3.8$ Hz, 1H), 4.99 (t, $J = 4.7$ Hz, 1H), 4.24 (s, 1H), 3.79 (d, $J = 3.2$ Hz, 1H), 3.55 (dt, $J = 11.7, 7.9$ Hz, 2H), 2.51 (s, 3H), 2.17 (ddd, $J = 12.8, 5.8, 3.8$ Hz, 1H), 2.10 (dt, $J = 13.1, 6.5$ Hz, 1H). ^{13}C NMR $\{^1\text{H}\}$ (101 MHz, DMSO) δ 163.6, 155.0, 140.7, 139.4, 134.9, 129.9, 126.0, 125.6, 107.9, 87.7, 85.6, 70.5, 61.4, 41.0, 14.8. **Anal Calcd.** For $\text{C}_{15}\text{H}_{17}\text{N}_3\text{O}_4\text{S}$: C, 55.00; H, 5.48; N, 12.03; S, 9.18 Found C, 55.15; H, 5.19; N, 12.13; S, 9.21.




references


- 1) V. Gayakhe, A. V. Ardhapure, A. R. Kapdi, Y. S. Sanghvi, J. L. Serrano, *J. Org. Chem.*, 2016, **81**, 2713–2729.
- 2) A. R. Kapdi, V. Gayakhe, Y. S. Sanghvi, J. García, P. Lozano, I. da Silva, J. Pérez, J. L. Serrano, *RSC Adv.*, 2014, **4**, 17567–17572

2). Spectroscopic characterization of complexes.....S19


Experimental characterization of $[\text{PdCl}_2(\text{THPEN})]$ (1).



IR of $[\text{PdCl}_2(\text{THPEN})]$ (1).




RMN- ^1H in $\text{dmsO}-d_6$ of $[\text{PdCl}_2(\text{THPEN})]$ (1).




ESI-MS of $[\text{PdCl}_2(\text{THPEN})]$ (**1**).


Experimental characterization of $[\text{Pd}(\text{phthal})_2(\text{THPEN})]$ (2).



IR of $[\text{Pd}(\text{phthal})_2(\text{THPEN})]$ (2).




RMN- ^1H in D_2O of $[\text{Pd}(\text{phthal})_2(\text{THPEN})]$ (2).




ESI-MS of $[\text{Pd}(\text{phthal})_2(\text{THPEN})]$ (**2**)


Experimental characterization of $[\text{Pd}(\text{sacc})_2(\text{THPEN})]$ (**3**).



IR of $[\text{Pd}(\text{sacc})_2(\text{THPEN})]$ (**3**).




RMN- ^1H in D_2O of $[\text{Pd}(\text{sacc})_2(\text{THPEN})]$ (**3**).




ESI-MS of $[\text{Pd}(\text{sacc})_2(\text{THPEN})]$ (**3**).


Experimental characterization of $[\text{Pd}(\text{sacc})_2(\text{THEEN})]$ (4).



IR of $[\text{Pd}(\text{sacc})_2(\text{THEEN})]$ (4).



RMN- ^1H in D_2O of $[\text{Pd}(\text{sacc})_2(\text{THEEN})]$ (4).



ESI-MS of $[\text{Pd}(\text{sacc})_2(\text{THEEN})]$ (**4**).